Palmitoylethanolamide in CNS health and disease

Pharmacological Research

Volumn 86, Issue , 2014, Pages 32-41

  Mattace Raso, Giuseppina ^a   Russo, Roberto ^a   Calignano, Antonio ^a   Meli, Rosaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Acylethanolamide; Behavior; Food intake; Inflammation; Neurodegenerative disease; Pain; Peroxisome proliferator Activated receptor

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; CYCLOOXYGENASE 2; ENDOCANNABINOID; FATTY ACID AMIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; VANILLOID RECEPTOR 1; ANTIINFLAMMATORY AGENT; ETHANOLAMINE DERIVATIVE; NEUROPROTECTIVE AGENT; PALMITIC ACID DERIVATIVE;

ADAPTIVE IMMUNITY; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ANTIOXIDANT ACTIVITY; CHLORIDE CURRENT; CHRONIC PAIN; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME INHIBITION; EPILEPSY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEEDING BEHAVIOR; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; HYPERPOLARIZATION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INFLAMMATORY PAIN; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MURINE ENCEPHALOMYELITIS VIRUS INDUCED DEMYELINATING DISEASE; NERVE CELL EXCITABILITY; NEUROMODULATION; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; OBESITY; PAIN; PARKINSON DISEASE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVIEW; STEROIDOGENESIS; TOBACCO DEPENDENCE; TONIC SEIZURE; UPREGULATION; ANIMAL; CENTRAL NERVOUS SYSTEM; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; NEURODEGENERATIVE DISEASES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CENTRAL NERVOUS SYSTEM; ETHANOLAMINES; HUMANS; INFLAMMATION; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PAIN; PALMITIC ACIDS; PPAR ALPHA;

EID: 84905234957     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.05.006     Document Type: Review

References (151)

1. H. Cadas, S. Gaillet, M. Beltramo, L. Venance, and D. Piomelli Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP J Neurosci 16 1996 3934 3942 (Pubitemid 26176057)
2. H.S. Hansen, B. Moesgaard, H.H. Hansen, and G. Petersen N-Acylethanolamines and precursor phospholipids: relation to cell injury Chem Phys Lipids 108 2000 135 150
3. L. Aloe, A. Leon, and R. Levi-Montalcini A proposed autacoids mechanism controlling mastocyte behavior Agents Actions 39 1993 C145 C147
4. M.G. Balvers, K.C. Verhoeckx, J. Meijerink, H.M. Wortelboer, and R.F. Witkamp Measurement of palmitoylethanolamide and other N-Acylethanolamines during physiological and pathological conditions CNS Neurol Disord Drug Targets 12 2013 23 33
5. H.S. Hansen, B. Moesgaard, G. Petersen, and H.H. Hansen Putative neuroprotective actions of N-Acyl-ethanolamines Pharmacol Ther 95 2002 119 126 (Pubitemid 35232130)
6. L. Walter, A. Franklin, A. Witting, T. Moller, and N. Stella Astrocytes in culture produce anandamide and other acylethanolamides J Biol Chem 277 2002 20869 20876 (Pubitemid 34967395)
7. G.G. Muccioli, and N. Stella Microglia produce and hydrolyze palmitoylethanolamide Neuropharmacology 54 2008 16 22 (Pubitemid 350299394)
8. S.D. Skaper, A. Buriani, R. Dal Toso, L. Petrelli, S. Romanello, and L. Facci et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons Proc Natl Acad Sci USA 93 1996 3984 3989 (Pubitemid 26146721)
9. A. Franklin, S. Parmentier-Batteur, L. Walter, D.A. Greenberg, and N. Stella Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility J Neurosci 23 2003 7767 7775 (Pubitemid 37052344)
10. B.F. Cravatt, D.K. Giang, S.P. Mayfield, D.L. Boger, R.A. Lerner, and N.B. Gilula Molecular characterization of an enzyme that degrades neuromodulatory fatty-Acid amides Nature 384 1996 83 87 (Pubitemid 26374593)
11. N. Ueda, K. Tsuboi, and T. Uyama Metabolism of endocannabinoids and related N-Acylethanolamines: canonical and alternative pathways FEBS J 280 2013 1874 1894
12. S.G. Kinsey, S.T. O'Neal, J.Z. Long, B.F. Cravatt, and A.H. Lichtman Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay Pharmacol Biochem Behav 98 2011 21 27
13. L. Facci, R. Dal Toso, S. Romanello, A. Buriani, S.D. Skaper, and A. Leon Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide Proc Natl Acad Sci USA 92 1995 3376 3380
14. J. Lo Verme, J. Fu, G. Astarita, G. La Rana, R. Russo, and A. Calignano et al. The nuclear receptor peroxisome proliferator-Activated receptor alpha mediates the anti-inflammatory actions of palmitoylethanolamide Mol Pharmacol 67 2005 15-9
15. J. Lo Verme, R. Russo, G. La Rana, J. Fu, J. Farthing, and G. Mattace-Raso et al. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-Activated receptor-Alpha J Pharmacol Exp Ther 319 2006 1051 1061
16. S. Moreno, S. Farioli-Vecchioli, and M.P. Cerù Immunolocalization of peroxisome proliferator-Activated receptors and retinoid X receptors in the adult rat CNS Neurosci 123 2004 131 145 (Pubitemid 37518482)
17. G. D'Agostino, G. La Rana, R. Russo, O. Sasso, A. Iacono, and E. Esposito et al. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kB nuclear signalling in dorsal root ganglia Eur J Pharmacol 613 2009 54-9
18. H.S. Hansen Palmitoylethanolamide and other anandamide congeners Proposed role in the diseased brain Exp Neurol 224 2010 48 55
19. O. Sasso, G. La Rana, S. Vitiello, R. Russo, G. D'Agostino, and A. Iacono et al. Palmitoylethanolamide modulates pentobarbital-evoked hypnotic effect in mice: involvement of allopregnanolone biosynthesis Eur Neuropsychopharmacol 20 2010 195 206
20. O. Sasso, R. Russo, S. Vitiello, G. Mattace Raso, G. D'Agostino, and A. Iacono et al. Implication of allopregnanolone in the antinociceptive effect of N-palmitoylethanolamide in acute or persistent pain Pain 153 2012 33 41
21. G. Mattace Raso, E. Esposito, S. Vitiello, A. Iacono, A. Santoro, and G. D'Agostino et al. Palmitoylethanolamide stimulation induces allopregnanolone synthesis in C6 Cells and primary astrocytes: involvement of peroxisome-proliferator activated receptor-α J Neuroendocrinol 23 2011 591 600
22. S.D. Skaper, L. Facci, and P. Giusti Mast cells, glia and neuroinflammation: partners in crime Immunology 141 2014 314 327
23. H.S. Hansen, L. Lauritzen, A.M. Strand, A.M. Vinggaard, A. Frandsen, and A. Schousboe Characterization of glutamate-induced formation of N-Acylphosphatidylethanolamine and N-Acylethanolamine in cultured neocortical neurons J Neurochem 69 1997 753 761 (Pubitemid 27327979)
24. C. Berger, P.C. Schmid, W.R. Schabitz, M. Wolf, S. Schwab, and H.H.O. Schmid Massive accumulation of N-Acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? J Neurochem 88 2004 1159 1167 (Pubitemid 38280683)
25. W.R. Schäbitz, A. Giuffrida, C. Berger, A. Aschoff, M. Schwaninger, and S. Schwab et al. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study Stroke 33 2002 2112 2114 (Pubitemid 34840078)
26. S.D. Skaper, and L. Facci Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide Philos Trans R Soc Biol Sci 367 2012 3312 3325
27. L. De Petrocellis, J.B. Davis, and V. Di Marzo Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors FEBS Lett 506 2001 253 256 (Pubitemid 32964824)
28. R. Mechoulam, E. Fride, L. Hanus, T. Sheskin, T. Bisogno, and V. Di Marzo et al. Anandamide may mediate sleep induction Nature 389 1997 25 26 (Pubitemid 27387679)
29. D. Smart, K.O. Jonsson, S. Vandevoorde, D.M. Lambert, and C.J. Fowler Entourage' effects of N-Acyl ethanolamines at human vanilloid receptors Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism Br J Pharmacol 136 2002 452 458 (Pubitemid 34620526)
30. K.O. Jonsson, S. Vandevoorde, D.M. Lambert, G. Tiger, and C.J. Fowler Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide Br J Pharmacol 133 2001 1263 1275 (Pubitemid 32783487)
31. L. De Petrocellis, C.J. Chu, A.S. Moriello, J.C. Kellner, J.M. Walker, and V. Di Marzo Actions of two naturally occurring saturated N-Acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels Br J Pharmacol 143 2004 251 256 (Pubitemid 39315145)
32. W.S. Ho, D.A. Barrett, and M.D. Randall 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors Br J Pharmacol 155 2008 837 846
33. R.G. Pertwee, A.C. Howlett, M.E. Abood, S.P.H. Alexander, V. Di Marzo, and M.R. Elphick et al. International Union of Basic and Clinical Pharmacology LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2 Pharmacol Rev 62 2010 588 631
34. G. Godlewski, L. Offertáler, J.A. Wagner, and G. Kunos Receptors for acylethanolamides-GPR55 and GPR119 Prostaglandins Other Lipid Mediat 89 2009 105 111
35. E. Ryberg, N. Larsson, S. Sjögren, S. Hjorth, N.O. Hermansson, and J. Leonova et al. The orphan receptor GPR55 is a novel cannabinoid receptor Br J Pharmacol 152 2007 1092 1101 (Pubitemid 350166046)
36. H.A. Overton, A.J. Babbs, S.M. Doel, M.C. Fyfe, L.S. Gardner, and G. Griffin et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents Cell Metab 3 2006 167 175
37. H. Sharir, and M.E. Abood Pharmacological characterization of GPR55, a putative cannabinoid receptor Pharmacol Ther 126 2010 301 313
38. R.A. Ross The enigmatic pharmacology of GPR55 Trends Pharmacol Sci 30 2009 156 163
39. N.A.B. Balenga, E. Aflaki, J. Kargl, W. Platzer, R. Schroder, and S. Blattermann et al. GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils Cell Res 21 2011 1452 1469
40. Bonini JA. Methods of identifying compounds that binds to SNORF25 receptors. US Patent 2002;6,468,756.
41. J. Fu, S. Gaetani, F. Oveisi, J. Lo Verme, A. Serrano, and F. Rodríguez De Fonseca et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-Alpha Nature 425 2003 90 93 (Pubitemid 37101723)
42. M. Melis, G. Pillolla, A. Luchicchi, A.L. Muntoni, S. Yasar, and S.R. Goldberg et al. Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors J Neurosci 28 2008 13985 13994
43. A. Barana, I. Amorós, R. Caballero, R. Gómez, L. Osuna, and M.P. Lillo et al. Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner Cardiovasc Res 85 2010 56 67
44. I. Amorós, A. Barana, R. Caballero, R. Gómez, L. Osuna, and M.P. Lillo et al. J Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner Mol Cell Cardiol 48 2010 201 210
45. U. Pannasch, K. Färber, C. Nolte, M. Blonski, S. Yan Chiu, and A. Messing et al. The potassium channels Kv1.5 and Kv1.3 modulate distinct functions of microglia Mol Cell Neurosci 33 2006 401 411 (Pubitemid 44820855)
46. K.M. Mullen, M. Rozycka, H. Rus, L. Hu, C. Cudrici, and E. Zafranskaia et al. Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system Ann Neurol 60 2006 118 127
47. M.L. Bourdeau, F. Morin, C.E. Laurent, M. Azzi, and J.C. Lacaille Kv4.3-mediated A-type K+ currents underlie rhythmic activity in hippocampal interneurons J Neurosci 27 2007 1942 1953
48. A. Burkhalter, Y. Gonchar, R.L. Mellor, and J.M. Nerbonne Differential expression of I(A) channel subunits Kv4.2 and Kv4.3 in mouse visual cortical neurons and synapses J Neurosci 26 2006 12274 12282 (Pubitemid 44808395)
49. T.G. Kokate, M.K. Banks, T. Magee, S. Yamaguchi, and M.A. Rogawski Finasteride a 5alpha-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice J Pharmacol Exp Ther 288 1999 679 684 (Pubitemid 29119681)
50. J. Lo Verme, G. La Rana, R. Russo, A. Calignano, and D. Piomelli The search for the palmitoylethanolamide receptor Life Sci 77 2005 1685 1698 (Pubitemid 41073662)
51. P. Zheng Neuroactive steroid regulation of neurotransmitter release in the CNS: action, mechanism and possible significance Prog Neurobiol 89 2009 134 152
52. C.A. Dinarello Inflammatory cytokines: Interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases Curr Opin Immunol 3 1991 941 948
53. V. Raghavendra, and J.A. DeLeo The role of astrocytes and microglia in persistent pain Adv Mol Cell Biol 31 2004 951 966
54. E.D. Milligan, S.F. Maier, and L.R. Watkins Review: neuronal-glial interactions in central sensitization Sem Pain Med 1 2003 171 183 (Pubitemid 40418221)
55. S. Najjar, D. Pearlman, D.C. Miller, and O. Devinsky Refractory epilepsy associated with microglial activation Neurologist 17 2011 249 254
56. N. Sailasuta, K. Harris, T. Tran, and B. Ross Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study Neuropsychiatr Dis Treat 7 2011 495 499
57. A. Prat, M. Behrendt, E. Marcinkiewicz, S. Boridy, R.M. Sairam, and N.G. Seidah et al. A novel mouse model of Alzheimer's disease with chronic estrogen deficiency leads to glial cell activation and hypertrophy J Aging Res 2011 2011 251517
58. M. Song, J. Jin, J.E. Lim, J. Kou, A. Pattanayak, and J.A. Rehman et al. TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease J. Neuroinflammation 8 2011 92
59. S.H. Cho, B. Sun, Y. Zhou, T.M. Kauppinen, B. Halabisky, and P. Wes et al. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease J Biol Chem 286 2011 32713 32722
60. L. Fellner, K.A. Jellinger, G.K. Wenning, and N. Stefanova Glial dysfunction in the pathogenesis of a-synucleinopathies: emerging concepts Acta Neuropathol 121 2011 675 693
61. C. Barcia, C.M. Ros, V. Annese, A. Gómez, F. Ros-Bernal, and D. Aguado-Yera et al. IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease Cell Death Dis 2 2011 e142
62. S.H. Appel, W. Zhao, D.R. Beers, and J.S. Henkel The microglial- motoneuron dialogue in ALS Acta Myol 30 2011 4 8
63. B.J. Mitterauer Possible role of glia in cognitive impairment in schizophrenia CNS Neurosci Ther 17 2011 333 344
64. M. Hinwood, J. Morandini, T.A. Day, and F.R. Walker Evidence that microglia mediate the neurobiological effects of chronic psychological stress on the medial prefrontal cortex Cereb Cortex 22 2011 1442 1454
65. C.T. Ekdahl Microglial activation - tuning and pruning adult neurogenesis Front Pharmacol 3 2012 41
66. C. Rosano, A.L. Marsland, and P.J. Gianaros Maintaining brain health by monitoring inflammatory processes: a mechanism to promote successful aging Aging Dis 3 2012 16 33
67. F. González-Scarano, and G. Baltuch Microglia as mediators of inflammatory and degenerative diseases Annu Rev Neurosci 22 1999 219 240 (Pubitemid 29144887)
68. B.F. Cravatt, A. Saghatelian, E.G. Hawkins, A.B. Clement, M.H. Bracey, and A.H. Lichtman Functional disassociation of the central and peripheral fatty acid amide signaling systems Proc Natl Acad Sci USA 101 2004 10821 10826 (Pubitemid 38955826)
69. D. Fegley, S. Kathuria, R. Mercier, C. Li, A. Goutopoulos, and A. Makriyannis et al. Anandamide transport is independent of fatty-Acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172 Proc Natl Acad Sci USA 101 2004 8756 8761 (Pubitemid 38745844)
70. S. Patel, E.J. Carrier, W.S. Ho, D.J. Rademacher, S. Cunningham, and D.S. Reddy et al. The postmortal accumulation of brain N-Arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity J Lipid Res 46 2005 342 349 (Pubitemid 40271098)
71. N. Stella, and D. Piomelli Receptor-dependent formation of endogenous cannabinoids in cortical neurons Eur J Pharmacol 425 2001 189 196 (Pubitemid 32770066)
72. S. Cerrato, P. Brazis, M.F. della Valle, A. Miolo, and A. Puigdemont Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells Vet Immunol Immunopathol 133 2010 9 15
73. N. Ghafouri, B. Ghafouri, B. Larsson, M.V. Turkina, L. Karlsson, and C.J. Fowler et al. High levels of N-palmitoylethanolamide and N-stearoylethanolamide in microdialysate samples from myalgic trapezius muscle in women PLoS ONE 6 2011 e27257
74. S.D. Skaper, L. Facci, S. Romanello, and A. Leon Mast cell activation causes delayed neurodegeneration in mixed hippocampal cultures via the nitric oxide pathway J Neurochem 66 1996 1157 1166 (Pubitemid 26068390)
75. N.A. Simonian, and J.T. Coyle Oxidative stress in neurodegenerative diseases Annu Rev Pharmacol Toxicol 36 1996 83 106 (Pubitemid 26168695)
76. D. De Filippis, L. Luongo, M. Cipriano, E. Palazzo, M.P. Cinelli, and V. de Novellis et al. Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats Mol Pain 7 2011 3
77. B. Costa, F. Comelli, I. Bettoni, M.P. Colleoni, and G. Giagnoni The endogenous fatty acid amide, palmitoylethanolamide, has antiallodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARgamma receptors and neurotrophic factors Pain 139 2008 541 550
78. G. D'Agostino, G. La Rana, R. Russo, O. Sasso, A. Iacono, and E. Esposito et al. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-Activated receptor-Alpha agonist, modulates carrageenan-induced paw edema in mice J Pharmacol Exp Ther 322 2007 1137 1143 (Pubitemid 47295805)
79. N. Uceyler, K. Gobel, S.G. Meuth, S. Ortler, G. Stoll, and C. Sommer et al. Deficiency of the negative immune regulator B7-H1 enhances inflammation and neuropathic pain after chronic constriction injury of mouse sciatic nerve Exp Neurol 222 2010 153 160
80. K.A. Kigerl, J.C. Gensel, D.P. Ankeny, J.K. Alexander, D.J. Donnelly, and P.G. Popovich Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord J Neurosci 29 2009 13435 13444
81. L. Di Cesare Mannelli, G. D'Agostino, A. Pacini, R. Russo, M. Zanardelli, and C. Ghelardini et al. Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-Alpha-mediated mechanism Mediators Inflamm 2013 2013 328797
82. A.H. Ding, C.F. Nathan, and D.J. Stuehr Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production J Immunol 141 1988 2407 2412
83. A. Calignano, G. La Rana, A. Giuffrida, and D. Piomelli Control of pain initiation by endogenous cannabinoids Nature 394 1998 277 281 (Pubitemid 28335039)
84. A. Calignano, G. La Rana, and D. Piomelli Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide Eur J Pharmacol 419 2001 191 198 (Pubitemid 32568218)
85. de Luongo, V.L. Novellis, F. Guida, L. Cristino, E. Palazzo, and R. Russo et al. Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity Eur J Pharmacol 676 2012 41 50
86. S. Petrosino, E. Palazzo, V. de Novellis, T. Bisogno, F. Rossi, and S. Maione et al. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats Neuropharmacology 52 2007 415 422 (Pubitemid 46127787)
87. M.D. Jhaveri, D. Richardson, I. Robinson, M.J. Garle, A. Patel, and Y. Sun et al. Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-Activated receptor-Alpha in a model of inflammatory pain Neuropharmacology 55 2008 85 93
88. B.N. Okine, K. Rea, W.M. Olango, J. Price, S. Herdman, and M.K. Madasu et al. A role for PPAR-α in the medial prefrontal cortex in formalin-evoked nociceptive responding in rats Br J Pharmacol 171 2014 1462 1471
89. C. Giordano, L. Cristino, L. Luongo, D. Siniscalco, S. Petrosino, and F. Piscitelli et al. TRPV1-dependent and -independent alterations in the limbic cortex of neuropathic mice: impact on glial caspases and pain perception Cereb Cortex 22 2012 2495 2518
90. B.C. Shyu, and B.A. Vogt Short-term synaptic plasticity in the nociceptive thalamic-Anterior cingulate pathway Mol Pain 5 2009 51
91. Y.F. Xie, F.Q. Huo, and J.S. Tang Cerebral cortex modulation of pain Acta Pharmacol Sin 30 2009 31 41
92. I.A. Khasabova, Y. Xiong, L.G. Coicou, D. Piomelli, and V. Seybold Peroxisome proliferator-Activated receptor α mediates acute effects of palmitoylethanolamide on sensory neurons J Neurosci 32 2012 12735 12743
93. M.J. Caterina, M.A. Schumacher, M. Tominaga, T.A. Rosen, J.D. Levine, and D. Julius The capsaicin receptor: a heat-Activated ion channel in the pain pathway Nature 389 1997 816 824 (Pubitemid 27462969)
94. S. Vandevoorde, K.O. Jonsson, C.J. Fowler, and D.M. Lambert Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide J Med Chem 46 2003 1440 1448 (Pubitemid 36512706)
95. P. Ambrosino, M.V. Soldovieri, C. Russo, and M. Taglialatela Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide Br J Pharmacol 168 2013 1430 1444
96. A. Romano, T. Cassano, B. Tempesta, S. Cianci, P. Dipasquale, and R. Coccurello et al. The satiety signal oleoylethanolamide stimulates oxytocin neurosecretion from rat hypothalamic neurons Peptides 49 2013 21 26
97. S. Gaetani, J. Fu, T. Cassano, P. Dipasquale, A. Romano, and L. Righettei et al. The fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin J Neurosci 30 2010 8096 8101
98. R. Russo, G. D'Agostino, G. Mattace Raso, C. Avagliano, C. Cristiano, and R. Meli et al. Central administration of oxytocin reduces hyperalgesia in mice: implication for cannabinoid and opioid systems Peptides 38 2012 81 88
99. G. Gimpl, and F. Fahrenholz The oxytocin receptor system: structure, function, and regulation Physiol Rev 81 2001 629 683 (Pubitemid 32267075)
100. J. Yang Intrathecal administration of oxytocin induces analgesia in low back pain involving the endogenous opiate peptide system Spine (Phila Pa, 1976) 19 1994 867 871 (Pubitemid 24136159)
101. C. Scuderi, G. Esposito, A. Blasio, M. Valenza, P. Arietti, and L. Steardo Jr. et al. Palmitoylethanolamide counteracts reactive astrogliosis induced by b-Amyloid peptide J Cell Mol Med 15 2011 2664 2674
102. G. D'Agostino, R. Russo, C. Avagliano, C. Cristiano, R. Meli, and A. Calignano Palmitoylethanolamide protects against the amyloid-b25-35-induced learning and memory impairment in mice, an experimental model of Alzheimer disease Neuropsychopharmacology 37 2012 1784 1792
103. C. Scuderi, M. Valenza, C. Stecca, G. Esposito, M.R. Carratu, and L. Steardo Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator- Activated receptor-A J Neuroinflammation 9 2012 49
104. C. Scuderi, and L. Steardo Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease CNS Neurol Disord Drug Targets 12 2013 62 69
105. D. Baker, G. Pryce, J.L. Croxford, P. Brown, R.G. Pertwee, and A. Makriyannis et al. Endocannabinoids control spasticity in a multiple sclerosis model FASEB J 15 2001 300 302
106. E.M. Chastain, D.S. Duncan, J.M. Rodgers, and S.D. Miller The role of antigen presenting cells in multiple sclerosis Biochim Biophys Acta 1812 2011 265 274
107. F. Loria, S. Petrosino, L. Mestre, A. Spagnolo, F. Correa, and M. Hernangomez et al. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide Eur J Neurosci 28 2008 633 641
108. T. Bisogno, A. Martire, S. Petrosino, P. Popoli, and V. Di Marzo Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease Neurochem Int 52 2008 307 313 (Pubitemid 350235708)
109. L. Jean-Gilles, S. Feng, C.R. Tench, V. Chapman, D.A. Kendall, and D.A. Barrett et al. Plasma endocannabinoid levels in multiple sclerosis J Neurological Sci 287 2009 212 215
110. Y. Yang, A.R. Gocke, A. Lovett-Racke, P.D. Drew, and M.K. Racke PPAR alpha regulation of the immune response and autoimmune encephalomyelitis PPAR Res 2008 2008 546753
111. M.T. Heneka, and G.E. Landreth PPARs in the brain Biochim Biophys Acta 1771 2007 1031 1045 (Pubitemid 47208548)
112. S.E. O'Sullivan Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-Activated receptors Br J Pharmacol 152 2007 576 582 (Pubitemid 350034977)
113. E. Esposito, D. Impellizzeri, E. Mazzon, I. Paterniti, and S. Cuzzocrea Neuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's disease PLoS ONE 7 2012 e41880
114. L. Luongo, F. Guida, S. Boccella, G. Bellini, L. Gatta, and F. Rossi et al. Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal lial/microglial phenotypical changes in mice CNS Neurol Disord Drug Targets 12 2013 45 54
115. M. Schomacher, H.D. Muller, C. Sommer, S. Schwab, and W.R. Schabitz Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia Brain Res 1240 2008 213 220
116. Y. Sun, S.P. Alexander, M.J. Garle, C.L. Gibson, K. Hewitt, and S.P. Murphy et al. Cannabinoid activation of PPARalpha; a novel neuroprotective mechanism Br J Pharmacol 152 2007 734 743 (Pubitemid 350034991)
117. D. Garcia-Ovejero, A. Arevalo-Martin, S. Petrosino, F. Docagne, C. Hagen, and T. Bisogno et al. The endocannabinoid system is modulated in response to spinal cord injury in rats Neurobiol Dis 33 2009 57 71
118. T. Genovese, E. Esposito, E. Mazzon, R. Di Paola, R. Meli, and P. Bramanti et al. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury J Pharmacol Exp Ther 326 2008 12 23 (Pubitemid 351872139)
119. E. Esposito, I. Paterniti, E. Mazzon, T. Genovese, R. Di Paola, and M. Galuppo et al. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury Brain Behav Immun 25 2011 1099 1112
120. P. Campolongo, B. Roozendaal, V. Trezza, V. Cuomo, G. Astarita, and J. Fu et al. Fat-induced satiety factor oleoylethanolamide enhances memory consolidation Proc Natl Acad Sci USA 106 2009 8027 8031
121. C. Mazzola, J. Medalie, M. Scherma, L.V. Panlilio, M. Solinas, and G. Tanda et al. Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-Alpha nuclear receptors Learn Mem 16 2009 332 337
122. K. Monory, F. Massa, M. Egertová, M. Eder, H. Blaudzun, and R. Westenbroek et al. The endocannabinoid system controls key epileptogenic circuits in the hippocampus Neuron 51 2006 455 466 (Pubitemid 44209321)
123. D.M. Lambert, S. Vandevoorde, G. Diependaele, S.J. Govaerts, and A.R. Robert Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice Epilepsia 42 2001 321 327 (Pubitemid 32275910)
124. A.H. Sheerin, X. Zhang, D.M. Saucier, and M.E. Corcoran Selective antiepileptic effects of N-palmitoylethanolamide, a putative endocannabinoid Epilepsia 45 2004 1184 1188 (Pubitemid 39350330)
125. D.S. Reddy, and M.A. Rogawski Neurosteroids-endogenous regulators of seizure susceptibility and role in the treatment of epilepsy J.L. Noebels, M. Avoli, M.A. Rogawski, R.W. Olsen, A.V. Delgado-Escueta, Jasper's Basic Mechanisms of the Epilepsies [Internet] 4th ed. 2012 National Center for Biotechnology Information (US) Bethesda, MD
126. R. Citraro, E. Russo, E.D. Di Paola, G.F. Ibbadu, S. Gratteri, and R. Marra et al. Effects of some neurosteroids injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy Neuropharmacology 50 2006 1059 1071 (Pubitemid 43810125)
127. R. Citraro, E. Russo, F. Scicchitano, C.M. van Rijn, D. Cosco, and C. Avagliano et al. Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy Neuropharmacology 69 2013 115 126
128. D.A. Karanian, S.L. Karim, J.T. Wood, J.S. Williams, S. Lin, and A. Makriyannis et al. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage J Pharmacol Exp Ther 322 2007 1059 1066 (Pubitemid 47295815)
129. A. Castañe, F. Berrendero, and R. Maldonado The role of the cannabinoid system in nicotine addiction Pharmacol Biochem Behav 81 2005 381 386 (Pubitemid 40807135)
130. B. Le Foll, B. Forget, H.J. Aubin, and S.R. Goldberg Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies Addict Biol 13 2008 239 252 (Pubitemid 351692986)
131. M. Melis, S. Scheggi, G. Carta, C. Madeddu, S. Lecca, and A. Luchicchi et al. PPARα regulates cholinergic-driven activity of midbrain dopamine neurons via a novel mechanism involving α7 nicotinic acetylcholine receptors J Neurosci 3 2013 6203 6211
132. M. Melis, S. Carta, L. Fattore, S. Tolu, S. Yasar, and S.R. Goldberg et al. Peroxisome proliferator-Activated receptors-Alpha modulate dopamine cell activity through nicotinic receptors Biol Psychiatry 68 2010 256 264
133. T. Varga, Z. Czimmerer, and Nagy LPPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation Biochim Biophys Acta 1812 2011 1007 1022
134. S. Azhar, and G. Kelley PPARα: its role in the human metabolic syndrome Future Lipidol 2 2007 31 53 (Pubitemid 46805488)
135. P. Lefebvre, G. Chinetti, J.C. Fruchart, and B. Staels Sorting out the roles of PPARα in energy metabolism and vascular homeostasis J Clin Invest 116 2006 571 580 (Pubitemid 43326861)
136. J.N. Fiege, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli From molecular action to physiological outputs: peroxisome proliferator-Activated receptors are nuclear receptors at the crossroads of key cellular functions Prog Lipid Res 45 2006 120 159 (Pubitemid 43248732)
137. S.R. Pyper, N. Viswakarma, S. Yu, and J.K. Reddy PPARα: energy combustion, hypolipidemia, inflammation and cancer Nucl Recept Signal 8 2010 2002
138. T. Kainu, A.C. Wikstrom, J.A. Gustafsson, and M. Pelto-Huikko Localization of the peroxisome proliferator-Activated receptor in the brain NeuroReport 5 1994 2481 2485
139. A. Benani, T. Heurtaux, P. Netter, and A. Minn Activation of peroxisome proliferator-Activated receptor alpha in rat spinal cord after peripheral noxious stimulation Neurosci Lett 369 2004 59 63 (Pubitemid 39369503)
140. M.V. Chakravarthy, Y. Zhu, M. López, L. Yin, D.F. Wozniak, and T. Coleman et al. Brain fatty acid synthase activates PPARalpha to maintain energy homeostasis J Clin Invest 117 2007 2539 2552 (Pubitemid 47494355)
141. A.L. Hevener, J.M. Olefsky, D. Reichart, M.T. Nguyen, G. Bandyopadyhay, and H.Y. Leung et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones J Clin Invest 117 2007 1658 1669 (Pubitemid 46871350)
142. S. Kersten Regulation of nutrient metabolism and inflammation Results Probl Cell Differ 52 2010 13 25
143. W. Wahli, and L. Michalik PPARs at the crossroads of lipid signaling and inflammation Trends Endocrinol Metab 23 2012 351 363
144. G.S. Hotamisligil, and E. Erbay Nutrient sensing and inflammation in metabolic diseases Nat Rev Immunol 8 2008 923 934
145. L. Michalik, and W. Wahli PPARs mediate lipid signaling in inflammation and cancer PPAR Res 2008 2008 134059
146. F. Rodríguez de Fonseca, M. Navarro, R. Gómez, L. Escuredo, F. Nava, and J. Fu et al. An anorexic lipid mediator regulated by feeding Nature 414 2001 209 212 (Pubitemid 33051235)
147. G. Mattace Raso, A. Santoro, R. Russo, R. Simeoli, O. Paciello, and C. Di
148. E.H. Jang, C.S. Park, S.K. Lee, J.E. Pie, and J.H. Kang Excessive nitric oxide attenuates leptin mediated signal transducer and activator of transcription 3 activation Life Sci 80 2007 609 617
149. R. Wang, and A.G. Swick Identification and characterization of a leptin-responsive neuroblastoma cell line Biochem Biophys Res Commun 379 2009 835 839
150. E. Murillo-Rodriguez, F. Désarnaud, and O. Prospéro- García Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat Life Sci 30 79 2006 30 37
151. A.A. Izzo, F. Piscitelli, R. Capasso, P. Marini, L. Cristino, and S. Petrosino et al. Basal and fasting/refeeding-regulated tissue levels of endogenous PPAR-Alpha ligands in Zucker rats Obesity (Silver Spring) 18 2010 55 62